When a young student of Shirebrook Grammar School in Chesterfield, England, developed a keen interest in the translated classics of Russian literature, he relished, above all, the works of Dostoevsky, albeit without much understanding of the author’s contemporary world. Following the call of life circumstances, the young man enrolled as a university student in history without giving it much thought to a permanent career. Politically, he seemed to lean left, primarily as a reaction to the political environment prevailing at Keele University. He took on intense Russian language classes and spent many hours at the Russian bookstore on Charing Cross Road, immersed in the works of Lenin and Trotsky – an illusion he had yet to dispel.
E-Mail Interim analysis from phase 3 trial of nearly 20,000 participants suggests efficacy of two-dose regimen of the adenovirus-based vaccine is 91.6% against symptomatic COVID-19 - trial reports 16 COVID-19 cases in the vaccine group (0.1% [16/14,964) and 62 cases (1.3% [62/4,902]) in the placebo group. No serious adverse events were deemed to be associated with vaccination, and most reported adverse events were mild, including flu-like symptoms, pain at injection site and weakness or low energy. Sub-analysis of 2,000 adults older than 60 years suggests the vaccine is similarly effective and well tolerated in this group. Trial is ongoing and aiming to include a total of 40,000 participants - monitoring of safety and efficacy continues.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic .
Algernon PharmaceuticalsFebruary 1, 2021 GMT
VANCOUVER, British Columbia, Feb. 01, 2021 (GLOBE NEWSWIRE) Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that it has established a clinical research program for the treatment of stroke focused on AP-188 (“N,N-Dimethyltryptamine or DMT”), a known psychedelic compound that is part of the tryptamine family (other drugs in the tryptamine family include psilocybin and psilocin). Algernon plans to be the first company globally to pursue DMT for stroke in humans and is planning to begin a clinical trial as soon as possible in 2021.
Peer-reviewed / Simulation or Modelling / People
A new modelling study has estimated that from 2000 to 2030 vaccination against 10 major pathogens - including measles, rotavirus, HPV and hepatitis B - will have prevented 69 million deaths in low-income and middle-income countries (LMICs).
The study estimated that, as a result of vaccination programmes, those born in 2019 will experience 72% lower mortality from the 10 diseases over their lifetime than if there was no immunisation.
The greatest impact of vaccination was estimated to occur in children under five - mortality from the 10 diseases in this age group would be 45% higher than currently observed in the absence of vaccination, according to the research.
In 15 out of 17 minority ethnic groups, health-related quality of life in older age (over 55 year-olds) was worse on average for either men, women, or both, than for White British people according to an observational study published in The Lancet Public Health journal.